Today, the screeners at HealthTechMovers.com picked up 3 HealthTech Stocks up over 99% past 10 days and have been added to our watchlist. These are very volatile stocks so please do your own research before you make any investments. While we list the ratings of various 3rd party services, we're not recommending these stocks and we're not paid by the featured tickers, we simply report the big movers. If the editor has a position, it will be noted below the charts.
WallStreetMovers.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
Summary: InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.
Recent IFRX Stock Price (approx 10:00am EST.): $3.03
Previous Close for IFRX Stock: $3.11
Percentage Price Change Past 10 Days for IFRX stock: +124
%
TipRanks.com reports that InflaRx stock currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating for IFRX stock with an average price target is $5.00.
Click here to get the full story on IFRX stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company's product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States.
Recent ARDS Stock Price (approx 10:00am EST.): $2.24
Previous Close for ARDS Stock: $2.29
Percentage Price Change Past 10 Days for ARDS stock: +99%
Click here to get the full story on ARDS stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. The company's product candidate includes CBP-201. Connect Biopharma Holdings Limited is based in TAICANG, China.
Recent CNTB Stock Price (approx 10:00am EST.): $1.43
Previous Close for CNTB Stock: $1.63
Percentage Price Change Past 10 Days for CNTB stock: +99%
TipRanks.com reports that Connect Biopharma Holdings stock currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating for CNTB stock with an average price target is $5.00.
Click here to get the full story on CNTB stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Just a reminder, one resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
The other great tool for charting is TradingView.com, so you might want to check that out too.
The information in this article was pulled from third part services. The prices listed above are not real-time and will be delayed at least 15 minutes.
WallStreetMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to WallStreetMovers.com.